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Abstract
Background. Klotho and ﬁbroblast growth factor 23
(FGF23) are key regulators of mineral metabolism in
renal insufﬁciency. FGF23 levels have been shown to in-
crease early in chronic kidney disease (CKD); however,
the corresponding soluble Klotho levels at the different
CKD stages are not known.
Methods. Soluble Klotho, FGF23, parathyroid hormone
(PTH), 1,25-dihydroxy vitamin D3 (1,25D) and other
parameters of mineral metabolism were measured in an
observational cross-sectional study in 87 patients. Locally
weighted scatter plot smoothing function of these par-
ameters were plotted versus estimated glomerular ﬁltration
rate (eGFR) to illustrate the pattern of the relationship.
Linear and non-linear regression analyses were performed
to estimate changes in mineral metabolism parameters per
1 mL/min/1.73 m2 decline.
Results. In CKD 1–5, Klotho and 1,25D linearly decreased,
whereas both FGF23 and PTH showed a baseline at early
CKD stages and then a curvilinear increase. Crude mean
Klotho level declined by 4.8 pg/mL (95% CI 3.5–6.2 pg/mL,
P < 0.0001) and 1,25D levels by 0.30 ng/L (95% CI 0.18–
0.41 ng/L, P < 0.0001) as GFR declined by 1 mL/min/
1.73 m2. After adjustment for age, gender, serum 25-hy-
droxyvitamin D levels and concomitant medications
(calcium, supplemental vitamin D and calcitriol), we esti-
mated that the mean Klotho change was 3.2 pg/mL (95%
CI 1.2–5.2 pg/mL, P = 0.0019) for each 1 mL/min/1.73 m2
GFR change. FGF23 departed from the baseline at an
eGFR of 47 mL/min/1.73 m2 (95% CI 39–56 mL/min/
1.73 m2), whereas PTH departed at an eGFR of 34 mL/
min/1.73 m2 (95% CI 19–50 mL/min/1.73 m2).
Conclusions. Soluble Klotho and 1,25D levels decrease
and FGF23 levels increase at early CKD stages, whereas
PTH levels increase at more advanced CKD stages.
Keywords: chronic kidney disease (CKD); ﬁbroblast growth factor 23
(FGF23); Klotho; parathyroid hormone (PTH); 1,25-dihydroxyvitamin
D3 (1,25D)
Introduction
Klotho, expressed in the kidney [1, 2], parathyroid glands
[3, 4] and the choroid plexus [5], is a single transmem-
brane protein whose extracellular domain is cleaved by
the α-secretases ADAM 10 and 17 [6] to generate large
amounts of soluble Klotho into blood, urine and cere-
brospinal ﬂuid [7, 8]. Soluble Klotho activates ion chan-
nels TRPV5 and 6 in the nephron and the intestine [9,
10], and regulates the sodium-phosphate co-transporters
Type-2a and c (NaPiIIa and c) independently of ﬁbroblast
growth factor 23 (FGF23) [8].
Transmembrane Klotho acts as an important co-factor
for FGF23. FGF23, a phosphaturic hormone produced by
osteocytes, binds with only modest afﬁnity to the family
of FGF receptors (mainly Type 1, 3 and 4), whereas
in vivo Klotho is required for FGF23-mediated receptor
activation (mainly FGFR1c): it forms a complex with the
ﬁbroblast growth factor receptor (FGFR), thereby increas-
ing its afﬁnity for FGF23 [11, 12]. Thus, FGF23 and
Klotho synergize to regulate phosphate homeostasis [13]
by promoting renal phosphate excretion: they do so via
reduction in the number of NaPiIIa and NaPiIIc phosphate
co-transporters in the proximal tubule and reduction in
intestinal phosphate absorption, the latter following a
decreased renal synthesis of 1,25-dihydroxy vitamin D3
(1,25D) [14].
Rodent studies indicate that soluble Klotho levels in
urine and blood are highly correlated with renal Klotho
expression [15]. Studies in patients with chronic kidney
disease (CKD) or acute kidney injury indicate a decrease in
Klotho expression with decreasing GFR [16]; however,
these studies encompass a very limited number of patients
and Klotho levels were measured only semi-quantitatively
by western blots performed in concentrated urine samples.
Cross-sectional studies have shown that the curvilinear
slope of FGF23 versus estimated glomerular ﬁltration
rate (eGFR) ascends at CKD Stage 2–3, whereas that of
parathyroid hormone (PTH) versus eGFR ascends at CKD
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Stage 3 [17, 18]. However, at which CKD stage the fall of
serum Klotho occurs in patients with CKD remains a
matter of debate because a reliable assay for soluble
Klotho has not been available until recently [19, 20], and
data on the expression, function and regulatory mechan-
isms of soluble Klotho are scarce.
Our cross-sectional study is the ﬁrst systematic determi-
nation of serum levels of Klotho, FGF23, PTH, 1,25D
and other parameters of mineral metabolism performed in
a cohort of patients with chronic renal insufﬁciency at
CKD Stages 1–5. We examined the pattern of the respect-
ive changes in the mentioned parameters over the entire
range of CKD stages; the question is relevant as Klotho
or FGF23 may turn out to be important markers of early
kidney disease, of its progression as well as of its progno-
sis, besides the fact that both might become future thera-
peutic targets [21].
Materials and methods
Study participants and procedures
Eighty-seven patients at different stages of CKD not affected by polycys-
tic kidney disease nor having undergone previous kidney transplantation,
aged 18–84 years, were enrolled in the study. CKD patients were classi-
ﬁed according to eGFR; CKD Stage 1 (≥90 mL/min/1.73 m2), CKD
Stage 2 (60–89 mL/min/1.73 m2), CKD Stage 3 (30–59 mL/min/1.73
m2), CKD Stage 4 (15–29 mL/min/1.73 m2) and CKD Stage 5 [<15 mL/
min/1.73 m2 or dialysis (5D)]. Twenty-one healthy volunteers, aged 37–
62 years, without a medical history of renal disease, and screened nega-
tive for microhaematuria or microalbuminuria, served as control group.
Sitting blood pressure was measured by a nurse, a blood sample was
drawn and a spot urine sample (second fasting morning urine, after
voiding the ﬁrst urine of the day prior to the visit to the clinics) was
collected between 8 a.m. and 10 a.m. Haemodialysis patients were ana-
lysed at their steady-state condition: after the long interval, blood was
taken immediately after placing the dialysis needle and thus before start
of dialysis treatment. Residual renal function in CKD5D patients was
calculated according to guidelines for the measurement of renal function
[22] applying the formula of Daugirdas [23]. Brieﬂy, the mean of urea
and creatinine clearance, determined from 48-h urine collections and
normalized to 1.73 m2, were calculated. In anuric patients, the value was
set to zero.
The serum and urine aliquots were stored at −80°C. Blood was ana-
lysed for Klotho, FGF23, PTH, phosphate, ionized calcium, creatinine,
25-hydroxyvitamin D (25D) and 1,25D. Spot urine was analysed for
phosphate and creatinine.
The study was conducted according to the Declaration of Helsinki and
the guidelines of Good Clinical Practice (GCP), and was approved by the
local Ethics Committee. All patients gave written, informed consent.
Analytical methods
A novel enzyme-linked immunosorbent assay (ELISA) method detecting
human soluble Klotho has been developed ﬁrst by establishing a mono-
clonal antibody with strong afﬁnity for human Klotho protein, recogniz-
ing with high selectivity the tertiary protein structure of its extracellular
domain (Immuno-Biological Laboratories Co., Ltd., Japan). The estab-
lished protein detection method has been subsequently tested comparing
serum Klotho levels of healthy human volunteers with a human case
where the Klotho gene carries a mutation that hinders the expression of
Klotho in the test subject. The results of the analysis indicated that the
ELISA system can speciﬁcally detect and measure the circulating serum
Klotho levels in humans [20]. We further validated the assay in patients
affected by autosomal-dominant polycystic kidney disease: low serum
Klotho levels were found to constrain the phosphaturic effect of FGF23
and to correlate inversely with cyst growth and kidney volume [19]. The
respective intra-assay and intra-subject coefﬁcient of variations of Klotho
were 2.6 ± 1.1 and 5.6 ± 2.1%, respectively, in the present study.
The levels of carboxy-terminal FGF23 (second generation, Immuto-
pics Inc., San Clemente, CA, USA) and intact PTH (second generation,
Biomerica Inc., Newport Beach, CA, USA) were measured in serum by
ELISA according to the manufacturer’s protocol. As previously pub-
lished, we and others have shown that intact FGF23 and C-terminal
FGF23 levels closely correlate in early and late CKD stages
[14,18,24,25].
Serum 25D and 1,25D have been determined using the radioimmuno-
assay-kits from Diasorin (Stillwater, MN, USA) and Immunodiagnostic
Systems (Fountain Hills, AZ, USA), respectively. Phosphate concen-
trations were measured in serum and urine using standard methods. Crea-
tinine in serum and urine was assayed by the isotope dilution mass
spectrometry (IDMS) traceable modiﬁed Jaffé method. The glomerular
ﬁltration rate was estimated by using the CKD Epidemiology Collabor-
ation (CKD-EPI) equation [26]. Phosphate and creatinine (IDMS-trace-
able modiﬁed Jaffé method) concentrations were measured in serum and
urine. The ratio of the maximum rate of tubular phosphate reabsorption
to the glomerular ﬁltration rate (TmP/GFR) was calculated as follows:
TmP/GFR (mmol/L) ¼ PPUP  PCreaUCrea
where PP, UP, PCrea and UCrea refer to the plasma and urinary concen-
tration of phosphate and creatinine, respectively [27]. TmP/GFR allows
us to estimate the net renal phosphate transport and is referred to as the
theoretical renal phosphate threshold [28]. This corresponds to the theor-
etical lower limit of plasma phosphate below which all ﬁltered phosphate
would be absorbed (normal range 0.80–1.35 mmol/L).
Statistical analysis
Locally weighted scatter plot smoothing (LOWESS) function of Klotho,
FGF23, PTH, 1,25D and serum phosphate versus eGFR were ﬁtted by
the default function of the STATA version 11.2 software (STAT Corp.,
College Station, TX, USA) with a bandwidth of 0.8. LOWESS is a mod-
elling method designed to address situations in which the classical linear
regression procedures do not perform well [29]. At each point in the data
set, a low-degree polynomial is ﬁtted to a subset of the data, with expla-
natory variable values near the point whose response is being estimated.
LOWESS combines linear least squares regression with the ﬂexibility of
non-linear regression and does not require to specify a global function of
any form to ﬁt a model. LOWESS allows determination of a relationship
without having a speciﬁed global function of any form to ﬁt a model,
whereas linear models ‘force’ the line to ﬁt the a priori model, e.g. quad-
ratic function.
Based on the LOWESS shape, a linear model was ﬁtted for Klotho
and 1,25D and the crude mean change for each 1 mL/min/1.73 m2 eGFR
was estimated. Vitamin D increases Klotho expression in vivo in mice
[30] and in vitro in a variety of cell lines [31]. Therefore, the Klotho-
related data were adjusted by ﬁtting an a priori model containing the
following variables: vitamin D supplementation, 1,25D treatment,
calcium administration (calcium acetate, calcium supplement), calcium-
free phosphate binder (sevelamer, lanthanum) and serum 25D levels.
Thus, the estimated mean changes in Klotho and 1,25D were adjusted
for treatment with vitamin D compounds and 25D levels, covariates that
potentially inﬂuence these proﬁles over eGFR. The association between
FGF23 and PTH with eGFR was not linear and thus we ﬁtted a segmen-
ted model consisting of smoothly ﬁtted baseline and quadratic function
to estimate the departure point of the curve from the baseline.
In an additional analysis, differences among the CKD stages and
healthy volunteers were compared by one-way analysis of variance.
When the difference was signiﬁcant, statistical comparisons were done
by using Dunnett’s post hoc test with the healthy volunteers as a refer-
ence group. Spearman’s rank correlation coefﬁcient was calculated to
measure the statistical dependence between the two variables.
All P values were two-sided for the comparison between the groups
and values <0.05 were considered as statistically signiﬁcant. Statistical
analyses were performed using SAS statistical software, version 9.2.
(SAS Institute Inc., Cary, NC, USA).
Results
Patients were studied at the outpatient clinic of the Division
of Nephrology at the University Hospital of Zurich,
Switzerland, from March 2010 to May 2011. Table 1
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shows the characteristics of 87 CKD patients and 21
healthy volunteers. The patients were classiﬁed into CKD
stages according to the CKD EPI equation: 19% of the par-
ticipants belonged to CKD Stage 1, 22% to Stage 2, 13%
to Stage 3, 23% to Stage 4 and 23% to Stage 5 (18 of 20
patients on chronic haemodialysis treatment, median dialy-
sis vintage 1.4 years). Causes of nephropathies in CKD
patients were: hypertensive nephropathy (n = 20, 10%
biopsy conﬁrmed), IgA-nephropathy (n = 12, 83% biopsy
conﬁrmed), diabetic nephropathy (n = 6, 33% biopsy con-
ﬁrmed), focal segmental glomerulosclerosis (n = 10, 100%
biopsy conﬁrmed), lupus nephritis (n = 5, 80% biopsy con-
ﬁrmed), other glomerulonephritides (n = 13, 46% biopsy
conﬁrmed), other kidney diseases (n = 16, 81% biopsy
proven) and CKD of unknown aetiology (n = 5). Sup-
plemental Table 1 displays disease classiﬁcations according
to the CKD stages. In the CKD 4 and 5 strata, diabetic and
hypertensive patients were enriched. The frequency of
1,25D and phosphate binder treatment increased with ad-
vancing CKD stages. At any CKD stage, at least 40% of
the patients were supplemented with nutritional vitamin D
(Table 1). None of the patients were currently or had been
treated in the past with bisphosphonates.
Relationship between Klotho, GFR and parameters
of mineral metabolism
Klotho, 1,25D, FGF23 and PTH levels were plotted
versus eGFR and the respective relationships analysed by
the LOWESS function, a statistical technique without as-
sumption on the shape of the relationship.
Figure 1A reveals that serum Klotho and eGFR were
associated linearly. Klotho levels continuously declined
with progressive degree of severity of renal insufﬁciency;
this ﬁtted a linear model (r2 = 0.41, P < 0.0001) and it
was estimated that the crude mean Klotho level declined
by 4.8 pg/mL (95% CI 3.5–6.2 pg/mL, P < 0.0001) as
GFR declined by 1 mL/min. After adjustment for age,
gender, serum 25D levels, and concomitant medications
(calcium, supplemental vitamin D and calcitriol), we esti-
mated that the mean Klotho change was 3.2 pg/mL (95%
CI 1.2–5.2 pg/mL, P = 0.0019) for each 1 mL/min GFR
change. We noted that many patients had low 25D levels.
To rule out for the possibility that low Klotho levels
might just reﬂect vitamin D deﬁciency, we separately esti-
mated Klotho changes in subjects with serum 25D levels
of 20 μg/L and above (n = 37): crude and adjusted mean
Klotho level declined by 4.9 pg/mL (95% CI 3.0–6.8 pg/mL,
P < 0.0001) and by 3.6 pg/mL (95% CI 0.4–6.8 pg/mL,
P = 0.03), respectively, as GFR declined by 1 mL/min. We
obtained similar results when separately analysing sub-
jects without vitamin D supplementation (n = 43): crude
and adjusted mean Klotho level declined by 4.7 pg/mL
(95% CI 2.8–6.5 pg/mL, P < 0.0001) and by 3.7 pg/mL
(95% CI 0.9–6.5 pg/mL, P = 0.01), respectively, as GFR
declined by 1 mL/min.
We assessed the association of Klotho with other par-
ameters of mineral metabolism (Table 2). In the univariate
analysis, Klotho was associated with serum calcium,
phosphate, 1,25D, FGF23 and PTH. However, these
associations were attenuated after adjusting for age,
gender and eGFR. Age and eGFR remained indepen-
dently associated with Klotho, underlining the importance
of both factors when interpreting serum Klotho levels.
The serum Klotho levels among 17 haemodialysis
patients meeting the criteria for secondary hyperparathyr-
oidism (PTH >65 ng/mL, serum phosphate >1.1 mmol/L,
serum calcium < 2.6 mmol/L and calcitriol treatment<1
Table 1. Characteristics of patients with CKD and healthy volunteers (HV)
CKD 1 (n = 17) CKD 2 (n = 19) CKD 3 (n = 11) CKD 4 (n = 20) CKD 5 (n = 20) HV (n = 21)
Age, years 41 ± 14 40 ± 12 57 ± 15 64 ± 12 61 ± 17 48 ± 8
Sex, no. (%)
Female 7 (41) 12 (63) 6 (55) 9 (45) 8 (40) 9 (43)
Male 10 (59) 7 (37) 5 (45) 11 (55) 12 (60) 12 (57)
Body mass index, kg/ m2 28 ± 6 23 ± 5 28 ± 4 28 ± 6 24 ± 6 24 ± 2
Creatinine, mg/dL 0.8 ± 0.2 1.0 ± 0.2 1.5 ± 0.3 2.5 ± 0.7 6.6 ± 2.8 0.9 ± 0.1
eGFR, mL/min/1.73 m2 104.1 ± 11.3 81.1 ± 16.5 42.6 ± 6.0 25.3 ± 5.8 5.7 ± 4.9 91.2 ± 14.1
Blood pressure, mmHg
Systolic 139 ± 13 130 ± 13 144 ± 21 145 ± 19 138 ± 26 129 ± 15
Diastolic 83 ± 10 84 ± 8 78 ± 14 79 ± 12 69 ± 21 80 ± 13
Urinary protein excretion
Protein-to-creatinine ratio, g/mmol 0.04 (0.01,
0.06)
0.01 (0.01,
0.04)
0.03 (0.01,
0.06)
0.02 (0.01,
0.07)
NA 0.02 (0.01,
0.02)
Medication, no. (%)
25-Hydroxy-vitamin supplement 7 (41) 7 (37) 9 (82) 13 (65) 8 (40) 0
1,25-Dihydroxy vitamin D3
treatment
0 (0) 1 (5) 1 (9) 5 (25) 4 (20) 0
Calcium-free phosphate binder 0 (0) 0 (0) 0 (0) 2 (10) 9 (45) 0
Calcium administration 4 (24) 5 (26) 1 (9) 5 (25) 10 (50) 0
Bicarbonate supplement 0 (0) 0 (0) 0 (0) 4 (20) 1 (5) 0
Diuretics 1 (6) 2 (11) 4 (36) 14 (70) 6 (30) 0
Prednisone 3 (18) 6 (32) 4 (36) 2 (10) 3 (15) 0
eGFR, estimated glomerular ﬁltration rate. Values are means ± standard deviation and numbers (percentage).
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µg/week [32, 33]) were 463.4 ± 237.0 pg/mL (median
375.0 pg/mL, IQR 273.7–618.9 pg/mL).
Relationship between serum levels of 1,25D, FGF23
and PTH with eGFR
Figure 1B conﬁrms that 1,25D and eGFR are linearly
associated and 1,25D levels decline with progressive GFR
loss justifying the ﬁtting of a linear model. We estimated
that the crude mean 1,25D levels decrease by 0.30 ng/L
(95% CI 0.18–0.41 ng/L, P < 0.0001) as eGFR declines
by 1 mL/min. The adjustment for age, gender, serum 25D
levels and the concomitant medications did only margin-
ally change the estimated 1,25D slope: 0.30 ng/L per 1
mL eGFR (0.10–0.49 ng/L per 1 mL eGFR; P = 0.0036).
Based on the visual inspection of the LOWESS plots,
FGF23 and PTH were not linearly associated with eGFR.
Thus, we ﬁtted a segmented, non-linear model that con-
sists of two segments connected in a smooth fashion, and
estimated the departure point of the curve from the base-
line. The iterative optimization converges after six
(FGF23 versus eGFR) and seven (PTH versus eGFR) iter-
ations, respectively. We estimated that the FGF23 curve
departs from the baseline (81 RU/mL) at a GFR of 47
mL/min (95% CI 39–56 mL/min), whereas the PTH curve
departs from the baseline (58 ng/mL), at an eGFR of 34
mL/min (95% CI 19–50 mL/min). However, it is note-
worthy that, in their respective relationship to eGFR,
FGF23 and PTH both showed a baseline at approximately
CKD Stages 1–3 for PTH and 1–2 for FGF23 and an
exponential increase at higher respective CKD stages in
the LOWESS plots (Figure 1C and D), whereas the seg-
mented model estimated a later departure from the base-
line indicating a Type 2 error, pointing to the fact that the
Fig. 1. Scatter plot graphs of with LOWESS lines of (A) Klotho, (B) 1,25-dihydroxy-vitamin D3 (1,25D), (C) carboxy-terminal ﬁbroblast growth
factor 23 (FGF23) and (D) intact parathyroid hormone (PTH) versus estimated glomerular ﬁltration rate (eGFR) in CKD patients. Each symbol
represents one patient.
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study is underpowered for this speciﬁc type of analysis
(which was not the primary focus of the analysis).
Phosphate, calcium and 25-hydroxy vitamin D
Mean serum phosphate levels increased only modestly in
patients at higher CKD stages: 0.96 mmol/L ± 0.17 mmol/
L in CKD 1 to 1.69 mmol/L ± 0.48 mmol/L in CKD5
(Table 3). Hyperphosphataemia (>1.1 mmol/L) was
present in 46% of the participating subjects, mostly in
patients with CKD Stages 4 and 5, as expected. The
LOWESS function of serum phosphate versus eGFR indi-
cated a baseline at early CKD stages and an exponential
increase at advanced CKD stages (Figure 2A). The depar-
ture point of the curve from the baseline was at an eGFR
of 35 mL/min (95% CI 22–49 mL/min) estimated by
ﬁtting a segmented non-linear regression model. TmP/
GFR remained normal and unchanged for patients at
CKD Stage 1–3 and then declined at Stage 4.
The ionized calcium levels remained unchanged across
CKD Stages 1–5 and the LOWESS function remained
within the normal range (1.10–1.30 mmol/L) (Figure 2B).
The serum levels of 25D also remained unchanged across
CKD Stages 1–5 (Figure 2C).
Differences among the CKD stages and healthy
volunteers
Klotho levels were lower among CKD Stage 5 patients
compared with age-matched healthy volunteers when ap-
plying a post hoc test adjusted for multiple testing and
using volunteers as a reference group. The Klotho levels
decreased approximately by half from CKD 1 to 5 (mean
difference −504.1 pg/mL (95% CI −747.4 to −260.8;
Table 2. Association of Klotho levels with other serum parameters of mineral metabolism in CKD patients: β estimates and (P-values) of the
univariate and multivariate regression analyses
Regression models Calcium Phosphate 1,25-dihydroxy vitamin D3 FGF23
a PTH a
Univariate
Klothoa −0.3 ( < 0.0001) −0.2 (0.01) 0.003 (<0.001) −0.2 (<0.001) −0.2 (<0.001)
Multivariate
Klothoa −0.02 (0.9) −0.01 (0.2) 0.001 (0.5) −0.002 (1.0) 0.03 (0.7)
Age (years) −0.004 (0.01) −0.004 (0.01) 0.001 (0.01) −0.003 (0.01) −0.004 (0.01)
Gender (male = 1) 0.01 (0.03) 0.03 (0.04) 0.01 (0.7) 0.01 (0.7) 0.009 (0.8)
eGFRb 0.001 (0.02) 0.001 (0.03) 0.001 (0.03) 0.002 (0.06) 0.002 (0.03)
aLog transformed.
bEstimated GFR according to the CKD-EPI formula.
Table 3. Parameters of phosphate metabolism in patients with CKD and healthy volunteers (HV)
Parameter CKD 1 (n = 17) CKD 2 (n = 19) CKD 3 (n = 11) CKD 4 (n = 20) CKD 5 (n = 20) HV (n = 21)
Serum
Klotho, pg/mL 964.3 ± 398.8 820.2 ± 283.4 638.1 ± 128.7 539.7 ± 165.1 460.2 ± 222.8 1078.6 ± 1810.2
Q1/Median/Q3 703.2/880.1/
1159.8
616.2/749.3/
999.1
423.9/622.6/
684.9
415.1/490.2/
640.8
282.2/368.3/
612.9
428.7/600.3/
861.5
FGF23, RU/mL 89.9 ± 54.3 65.1 ± 41.7 137.7 ± 45.9 377.2 ± 370.3 1200.6 ± 416.4 24.8 ± 13.7
Q1/median/Q3 51.1/95.5/101.4 38.2/50.8/82.9 50.8/140.1/
161.3
141.6/307.0/
434.0
910.0/1356.7/
1586.4
18.3/24.2/32.4
PTH, ng/mL 43.0 ± 17.0 40.4 ± 16.6 87.4 ± 63.8 129.1 ± 71.2 422.8 ± 392.7 55.6 ± 25.4
Q1/median/Q3 32.7/42.3/52.8 31.2/39.6/45.9 25.9/76.6/88.1 87.2/119.4/
156.7
196.9/314.2/
492.4
36.4/46.2/67.1
25-Hydroxy-vitamin D, μg/L 15.1 ± 8.9 20.4 ± 8.2 17.6 ± 6.0 21.9 ± 12.5 25.9 ± 12.4 21.6 ± 9.1
Q1/median/Q3 8.5/15.4/20.8 14.7/20.9/24.0 7.9/19.3/19.8 12.7/18.8/27.3 16.7/26.2/34.1 15.7/18.5/25.6
1,25-Dihydroxy-vitamin D3, ng/L 48.5 ± 25.9 45.7 ± 19.6 31.7 ± 12.7 27.12 ± 8.7 21.8 ± 15.0 65.4 ± 24.4
Q1/median/Q3 34.3/41.6/55.4 29.8/48.0/51.7 13.0/35.4/42.3 19.3/30.4/33.0 13.2/13.8/26.5 48.9/61.6/79.4
Phosphate, mmol/L 0.96 ± 0.17 1.02 ± 0.24 1.01 ± 0.22 1.15 ± 0.21 1.69 ± 0.48 1.00 ± 0.19
Q1/median/Q3 0.84/0.96/1.08 0.85/1.02/1.24 0.62/1.03/1.11 1.04/1.09/1.30 1.33/1.58/1.99 0.86/0.97/1.14
Ionized calcium, mmol/L 1.20 ± 0.05 1.24 ± 0.09 1.23 ± 0.05 1.22 ± 0.06 1.19 ± 0.08 NA
Q1/median/Q3 1.18/1.20/1.21 1.20/1.22/1.25 1.18/1.22/1.24 1.17/1.21/1.25 1.14/1.17/1.22
Calcium, mmol/L 2.32 ± 0.13 2.32 ± 0.13 2.39 ± 0.16 2.36 ± 0.14 2.33 ± 0.17 2.22 ± 0.09
Q1/median/Q3 2.26/2.32/2.40 2.22/2.33/2.41 2.28/2.36/2.44 2.25/2.34/2.47 2.22/2.30/2.41 2.18/2.24/2.28
Spot urine
Phosphate, mmol/L 12.8 ± 5.8 16.5 ± 12.9 9.7 ± 4.6 12.5 ± 5.4 — 16.7 ± 12.6
Q1/median/Q3 8.1/13.1/16.1 4.1/15.3/21.2 5.4/8.7/11.2 9.4/11.3/15.9 7.9/14.2/19.2
TmP/GFR, mmol/L/GFR 0.85 ± 0.16 0.89 ± 0.23 0.86 ± 0.25 0.72 ± 0.16 — 0.87 ± 0.21
Q1/median/Q3 0.74/0.81/0.97 0.69/0.85/1.13 0.42/0.91/1.03 0.60/0.78/0.85 0.70/0.88/1.02
Q1, 0.25 quartile; Q3, 0.75 quartile; 1,25D, 1,25-dihydroxy-vitamin D3; FGF23, carboxy-terminal ﬁbroblast growth factor 23; PTH, intact
parathyroid hormone; TmP/GFR, tubular maximum phosphate reabsorption per millilitre of glomerular ﬁltrate.
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P < 0.05). Serum levels of FGF23 in patients at CKD
Stages 4 and 5 were different from those obtained in
healthy volunteers (P < 0.05), whereas for PTH the serum
levels were only different from healthy volunteers at CKD
Stage 5 (P < 0.05). Only patients at CKD Stage 5 had
serum phosphate levels different from those observed in
healthy volunteers, similar to what was seen for PTH.
TmP/GFR values were similar among CKD patients and
volunteers (Table 3).
Discussion
In our present study, we illustrate the concurrent respect-
ive patterns of serum levels of the six key actors which
govern mineral metabolism in renal insufﬁciency, i.e.
Klotho, 1,25D, FGF23, PTH, phosphate and calcium:
serum levels of soluble alpha-Klotho and 1,25D decrease
in parallel with the progressive decline in glomerular ﬁl-
tration rate, whereas serum levels of FGF23 rise
(Figure 3). All do so before a rise in serum levels of PTH
occurs. Ultimately, e.g. at CKD Stage 4 and onwards,
serum levels of phosphate start rising, whereas serum
levels of ionized calcium remain unchanged across all
CKD stages included in this cross-sectional study. The
study also conﬁrms the low levels of serum Klotho in
haemodialysis patients with secondary hyperparathyroid-
ism [34].
It is of importance to mention that the cross-sectional
study design precludes deﬁnitive conclusions on the tem-
poral sequence. Furthermore, the relatively low number of
study subjects and the substantial variation of PTH and
Fig. 2. Scatter plot graphs with LOWESS lines of (A) serum phosphate, (B) ionized calcium and (C) 25-hydroxy-vitamin D (25D), versus eGFR
in CKD patients. Each symbol represents one patient.
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FGF23 levels preclude a precise estimation of the depar-
ture from the baseline. However, it is noteworthy that the
sequence suggested by the present study on 87 patients
conﬁrms that recently published on 3879 patients by
Isakova et al. [18] who pointed to the fact that the rise in
serum FGF23 might precede the rise in serum PTH in the
course of development of renal insufﬁciency. As to the
rise in FGF23 itself in a state of Klotho deﬁciency, it has
been envisioned as the consequence of phosphorous
accumulation as recently demonstrated by preclinical
studies which showed the absence of said rise in Klotho
−/− mice fed a low phosphate diet [21]. However, several
investigators have observed a modest reduction in serum
phosphate during early CKD [31,34] and our own data
also point in this direction.
The present study illustrates the fact that serum levels
of both 1,25D and Klotho decline ‘hand-in-hand’ with
progression of renal insufﬁciency. Given the current limit-
ations of the respective techniques, it remains speculative
to declare which of both levels declines ﬁrst, i.e. what is
the cause and what is the consequence: on the one hand,
Tsujikama et al. suggested that Klotho might have an
enzymatic ability to modify a receptor or ligand autono-
mously inﬂuencing the activity of 1-alpha hydroxylase;
on the other hand, the same authors demonstrated that
1,25D itself modulates the expression of Klotho [31].
Earlier studies reported Klotho levels in CKD patients
and volunteers: on the one hand, Sugiura et al. [35]
reported serum Klotho levels of 1413 pg/mL among 30
elderly CKD patients (serum creatinine values of
1.63 ± 1.35 mg/dL) and 404 pg/mL among 10 healthy
adults, aged 20–44 years, suggesting an elevation of
Klotho in CKD patients. The Klotho levels of these
healthy volunteers are substantially lower than values
previously reported in the literature and thus may indicate
selection bias or technical errors. Although the CKD
stages of the patients were not reported, the negative
lower boundary of the 95% CI of the serum creatinine
values suggests that the CKD stages were not evenly dis-
tributed and thus the rather high mean Klotho level in
CKD is possibly due to an enrichment of patients at early
CKD stages. The fact that FGF23 levels were similar in
healthy volunteers and CKD patients further supports the
hypothesis that patients at CKD Stages 1 and 2 were se-
lected preferentially in that study. On the other hand,
Akimoto et al. [36] reported that the amount of urinary
Klotho levels correlated positively with residual glomeru-
lar function in 36 peritoneal dialysis patients, whereas an
association between serum Klotho levels and residual
function was not found. Similarly, we did not ﬁnd an
association between residual function and serum Klotho
levels among 13 non-anuric haemodialysis patients
(Spearman r = 0.2, P = 0.4); however, this is a subgroup
analysis that is most likely underpowered.
It has been postulated by some that an initial renal
tubular damage leads to down-regulation of the expression
of both Klotho and 1-alpha-hydroxylase, and that the
ensuing cascade comprising the rise in FGF23 and in
PTH is the consequence: indeed, insufﬁcient production
of Klotho, known to occur at the level of both the para-
thyroid gland and the nephron in condition of renal insuf-
ﬁciency [37, 38], leads to peripheral resistance to FGF23
at both anatomical sites, and FGF23 thus can no longer
suppress PTH secretion nor maintain phosphate homeo-
stasis, as already suggested by Kuro-o [17].
Alternatively, it has been suggested [18] that the initial
FGF23 increase in early CKD actually causes the down-
regulation of Klotho via reduced 1,25D. Therefore, further
studies, in particular prospective longitudinal studies,
remain to be carried out to clarify this point and to deter-
mine the temporal sequence of the observed hormonal
changes in as much as the vitamin D administration itself
might play a role.
In conclusion, our data elevate the newly assayable
serum level of soluble alpha-Klotho to the rank of poten-
tially important marker for early detection of kidney
damage and it triggers new hopes for effective monitoring
and future therapeutic interventions.
Supplementary data
Supplementary data are available online at http://ndt.
oxfordjournals.org.
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Fig. 3. Overlaid LOWESS lines for Klotho (pg/mL), 1,25D (ng/
L × 10−3), carboxy-terminal ﬁbroblast growth factor 23 (FGF23, RU/
mL), intact parathyroid hormone (PTH, ng/mL) and serum phosphate
(mol/L × 10−3) versus eGFR (mL/min/1.73 m2) in CKD patients.
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